Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models

Barbara Nuvoli, Andrea Sacconi, Giancarlo Cortese, Sabrina Germoni, Bruno Murer, Rossella Galati

Research output: Contribution to journalArticle

Abstract

This study aimed to investigate intratumoural estradiol and estrogen-receptors (ERa, ERβ and GPR30) in malignant pleural mesothelioma (MPM) to understand their function. Here, we report that immunohistochemistry of estradiol showed cytoplasmatic staining in 95% of fifty-seven human MPM samples with a trend toward a negative correlation between estradiol levels and the median post-diagnosis survival time. ERβ was only focally positive in 5.3% of cases, GPR30 and ERa were negative in our cases of MPM. GPR30 was detected mainly in glycosylated form in MPM cells. Moreover, G15, a GPR30 antagonist, induced MPM cell death. Altogether, these data suggest that MPM cells produce E2 interact with glycosylated forms of GPR30, and this facilitates tumour growth. Estradiol was found in MPM cells and plasma from mice mesothelioma xenografts. Concurrent reduction in tumour mass and plasmatic estradiol levels were observed in the mice treated with exemestane, suggesting that the reduction of E2 levels inhibit MPM growth. Thus, it appears that agents reducing estradiol levels could be useful to MPM therapy.

Original languageEnglish
Pages (from-to)47116-47126
Number of pages11
JournalOncotarget
Volume7
Issue number30
DOIs
Publication statusPublished - 2016

Fingerprint

Estradiol
Growth
Neoplasms
exemestane
Estradiol Receptors
In Vitro Techniques
Malignant Mesothelioma
Mesothelioma
Reducing Agents
Plasma Cells
Heterografts
Estrogen Receptors
Cell Death
Immunohistochemistry
Staining and Labeling
Survival

Keywords

  • Estradiol
  • Estrogen receptor a
  • Estrogen receptor β
  • GPR30
  • Mesothelioma

ASJC Scopus subject areas

  • Oncology

Cite this

Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models. / Nuvoli, Barbara; Sacconi, Andrea; Cortese, Giancarlo; Germoni, Sabrina; Murer, Bruno; Galati, Rossella.

In: Oncotarget, Vol. 7, No. 30, 2016, p. 47116-47126.

Research output: Contribution to journalArticle

Nuvoli, Barbara ; Sacconi, Andrea ; Cortese, Giancarlo ; Germoni, Sabrina ; Murer, Bruno ; Galati, Rossella. / Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models. In: Oncotarget. 2016 ; Vol. 7, No. 30. pp. 47116-47126.
@article{80d186d102474b828f8d7eee73f04ad5,
title = "Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models",
abstract = "This study aimed to investigate intratumoural estradiol and estrogen-receptors (ERa, ERβ and GPR30) in malignant pleural mesothelioma (MPM) to understand their function. Here, we report that immunohistochemistry of estradiol showed cytoplasmatic staining in 95{\%} of fifty-seven human MPM samples with a trend toward a negative correlation between estradiol levels and the median post-diagnosis survival time. ERβ was only focally positive in 5.3{\%} of cases, GPR30 and ERa were negative in our cases of MPM. GPR30 was detected mainly in glycosylated form in MPM cells. Moreover, G15, a GPR30 antagonist, induced MPM cell death. Altogether, these data suggest that MPM cells produce E2 interact with glycosylated forms of GPR30, and this facilitates tumour growth. Estradiol was found in MPM cells and plasma from mice mesothelioma xenografts. Concurrent reduction in tumour mass and plasmatic estradiol levels were observed in the mice treated with exemestane, suggesting that the reduction of E2 levels inhibit MPM growth. Thus, it appears that agents reducing estradiol levels could be useful to MPM therapy.",
keywords = "Estradiol, Estrogen receptor a, Estrogen receptor β, GPR30, Mesothelioma",
author = "Barbara Nuvoli and Andrea Sacconi and Giancarlo Cortese and Sabrina Germoni and Bruno Murer and Rossella Galati",
year = "2016",
doi = "10.18632/oncotarget.9964",
language = "English",
volume = "7",
pages = "47116--47126",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "30",

}

TY - JOUR

T1 - Reduction of estradiol in human malignant pleural mesothelioma tissues may prevent tumour growth, as implied by in in-vivo and in-vitro models

AU - Nuvoli, Barbara

AU - Sacconi, Andrea

AU - Cortese, Giancarlo

AU - Germoni, Sabrina

AU - Murer, Bruno

AU - Galati, Rossella

PY - 2016

Y1 - 2016

N2 - This study aimed to investigate intratumoural estradiol and estrogen-receptors (ERa, ERβ and GPR30) in malignant pleural mesothelioma (MPM) to understand their function. Here, we report that immunohistochemistry of estradiol showed cytoplasmatic staining in 95% of fifty-seven human MPM samples with a trend toward a negative correlation between estradiol levels and the median post-diagnosis survival time. ERβ was only focally positive in 5.3% of cases, GPR30 and ERa were negative in our cases of MPM. GPR30 was detected mainly in glycosylated form in MPM cells. Moreover, G15, a GPR30 antagonist, induced MPM cell death. Altogether, these data suggest that MPM cells produce E2 interact with glycosylated forms of GPR30, and this facilitates tumour growth. Estradiol was found in MPM cells and plasma from mice mesothelioma xenografts. Concurrent reduction in tumour mass and plasmatic estradiol levels were observed in the mice treated with exemestane, suggesting that the reduction of E2 levels inhibit MPM growth. Thus, it appears that agents reducing estradiol levels could be useful to MPM therapy.

AB - This study aimed to investigate intratumoural estradiol and estrogen-receptors (ERa, ERβ and GPR30) in malignant pleural mesothelioma (MPM) to understand their function. Here, we report that immunohistochemistry of estradiol showed cytoplasmatic staining in 95% of fifty-seven human MPM samples with a trend toward a negative correlation between estradiol levels and the median post-diagnosis survival time. ERβ was only focally positive in 5.3% of cases, GPR30 and ERa were negative in our cases of MPM. GPR30 was detected mainly in glycosylated form in MPM cells. Moreover, G15, a GPR30 antagonist, induced MPM cell death. Altogether, these data suggest that MPM cells produce E2 interact with glycosylated forms of GPR30, and this facilitates tumour growth. Estradiol was found in MPM cells and plasma from mice mesothelioma xenografts. Concurrent reduction in tumour mass and plasmatic estradiol levels were observed in the mice treated with exemestane, suggesting that the reduction of E2 levels inhibit MPM growth. Thus, it appears that agents reducing estradiol levels could be useful to MPM therapy.

KW - Estradiol

KW - Estrogen receptor a

KW - Estrogen receptor β

KW - GPR30

KW - Mesothelioma

UR - http://www.scopus.com/inward/record.url?scp=84982833770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982833770&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9964

DO - 10.18632/oncotarget.9964

M3 - Article

AN - SCOPUS:84982833770

VL - 7

SP - 47116

EP - 47126

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 30

ER -